​

Arcutis Biotherapeutics (ARQT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ARQT Stock Forecast

Arcutis Biotherapeutics (ARQT) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $34.00, with a high of $34.00 and a low of $34.00. This represents a 46.36% increase from the last price of $23.23.

- $7 $14 $21 $28 $35 High: $34 Avg: $34 Low: $34 Last Closed Price: $23.23

ARQT Stock Rating

Arcutis Biotherapeutics stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (83.33%), 2 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 2 10 0 Strong Sell Sell Hold Buy Strong Buy

ARQT Price Target Upside V Benchmarks

TypeNameUpside
StockArcutis Biotherapeutics46.36%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--5
Avg Price Target--$32.40
Last Closing Price$23.23$23.23$23.23
Upside/Downside--39.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26251--8
May, 26251--8
Apr, 26251--8
Mar, 26251--8
Feb, 26251--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 26, 2026Doug TsaoH.C. Wainwright$34.00$27.0125.88%46.36%
Nov 28, 2025Uy EarMizuho Securities$37.00$30.9619.51%59.28%
Oct 30, 2025Richard LawGoldman Sachs$29.00$25.4114.13%24.84%
Oct 29, 2025Douglas TsaoH.C. Wainwright$30.00$24.9520.24%29.14%
Oct 29, 2025Uy EarMizuho Securities$32.00$24.9528.26%37.75%
Mar 11, 2025Jefferies$19.00$15.4922.66%-18.21%
Dec 30, 2024Douglas TsaoH.C. Wainwright$19.00$14.2033.80%-18.21%
May 15, 2024Serge BelangerNeedham$18.00$8.13121.40%-22.51%
May 15, 2024Uy EarMizuho Securities$18.00$8.13121.40%-22.51%
Jan 02, 2024Mizuho Securities$8.00$3.43133.24%-65.56%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 26, 2026H.C. WainwrightBuyBuyhold
Oct 30, 2025Goldman SachsNeutralNeutralhold
Oct 29, 2025H.C. WainwrightBuyBuyhold
Aug 07, 2025Cowen & Co.BuyBuyhold
Mar 11, 2025JefferiesBuyBuyhold
Dec 30, 2024H.C. WainwrightBuyinitialise
Aug 28, 2024NeedhamBuyBuyhold
Aug 28, 2024JefferiesBuyinitialise
Aug 15, 2024Cowen & Co.BuyBuyhold
Jul 10, 2024NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-5 $-3 $-1 $1 $3 $4 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.66$-3.78$-1.16$-0.13---
Avg Forecast$-5.93$-3.92$-1.32$-0.83$0.05$1.51$2.44
High Forecast$-4.99$-3.81$-1.18$-0.56$0.20$3.23$2.82
Low Forecast$-6.73$-4.02$-1.38$-0.96$-0.11$0.14$2.15
Surprise %-4.55%-3.57%-12.12%-84.34%---

Revenue Forecast

$0 $180M $360M $540M $720M $900M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.69M$59.61M$196.54M$376.07M---
Avg Forecast$2.97M$57.58M$185.46M$288.65M$423.15M$635.90M$788.81M
High Forecast$3.28M$64.49M$190.80M$311.07M$427.21M$712.20M$883.44M
Low Forecast$2.61M$52.28M$181.24M$267.54M$419.09M$577.34M$716.17M
Surprise %23.99%3.52%5.97%30.29%---

Net Income Forecast

$-500M $-350M $-200M $-50M $100M $250M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-311.46M$-262.14M$-140.04M$-16.14M---
Avg Forecast$-411.14M$-271.19M$-88.60M$-52.46M$3.08M$157.37M$168.97M
High Forecast$-345.49M$-263.71M$-81.47M$-38.68M$13.99M$223.66M$195.32M
Low Forecast$-466.18M$-278.68M$-95.73M$-66.23M$-7.84M$9.65M$148.74M
Surprise %-24.24%-3.34%58.05%-69.23%---

ARQT Forecast FAQ

Is Arcutis Biotherapeutics stock a buy?

Arcutis Biotherapeutics stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Arcutis Biotherapeutics is a favorable investment for most analysts.

What is Arcutis Biotherapeutics's price target?

Arcutis Biotherapeutics's price target, set by 12 Wall Street analysts, averages $34 over the next 12 months. The price target range spans from $34 at the low end to $34 at the high end, suggesting a potential 46.36% change from the previous closing price of $23.23.

How does Arcutis Biotherapeutics stock forecast compare to its benchmarks?

Arcutis Biotherapeutics's stock forecast shows a 46.36% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Arcutis Biotherapeutics over the past three months?

  • June 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Arcutis Biotherapeutics’s EPS forecast?

Arcutis Biotherapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $0.05, marking a -138.46% decrease from the reported $-0.13 in 2025. Estimates for the following years are $1.51 in 2027, and $2.44 in 2028.

What is Arcutis Biotherapeutics’s revenue forecast?

Arcutis Biotherapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $423.15M, reflecting a 12.52% increase from the reported $376.07M in 2025. The forecast for 2027 is $635.9M, and $788.81M for 2028.

What is Arcutis Biotherapeutics’s net income forecast?

Arcutis Biotherapeutics's net income forecast for the fiscal year ending in December 2026 stands at $3.08M, representing a -119.07% decrease from the reported $-16.141M in 2025. Projections indicate $157.37M in 2027, and $168.97M in 2028.